Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

BackgroundPatients with locally advanced prostate cancer (LAPCa) received docetaxel-based neoadjuvant chemo-hormonal therapy (NCHT) had better clinical outcomes after surgery compared to neoadjuvant hormonal therapy (NHT) groups, but not all patients experienced favorable clinical outcomes with NCHT...

Full description

Bibliographic Details
Main Authors:	Yinjie Zhu, Liancheng Fan, Hanjing Zhu, Yiming Gong, Chenfei Chi, Yanqing Wang, Jiahua Pan, Baijun Dong, Wei Xue
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	predictive signature locally advanced prostate cancer transcriptomic profiling neoadjuvant chemo-hormonal therapy neoadjuvant hormonal therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.963411/full

Similar Items

Effect of Neoadjuvant Hormonal Therapy on the Postoperative Course for Patients Undergoing Robot-Assisted Radical Prostatectomy
by: Mahmoud Farzat, et al.
Published: (2023-04-01)

Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer
by: David M. Marcus, et al.
Published: (2013-12-01)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2020-05-01)

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression
by: Krishan R. Jethwa, et al.
Published: (2016-11-01)

Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-04-01)

Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01)

Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors
by: Maria Carolina Gouveia, et al.
Published: (2022-12-01)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
by: Naiki Taku, et al.
Published: (2012-12-01)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
by: Ailin Lan, et al.
Published: (2022-08-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-09-01)

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-07-01)

Neoadjuvant Systemic Treatment of Primary Angiosarcoma
by: Kimberley M. Heinhuis, et al.
Published: (2020-08-01)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
by: Marron TU, et al.
Published: (2022-06-01)

A trio of tumor suppressor miRNA downregulates CREB5 dependent transcription to modulate neoadjuvant hormonal therapy sensitivity
by: Xueli Wang, et al.
Published: (2023-02-01)

The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis
by: Yaling Wang, et al.
Published: (2020-01-01)

Neoadjuvant treatment for pancreatic cancer: Controversies and advances
by: Douglas Dias e Silva, et al.
Published: (2024-01-01)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
by: Gizem Oner, et al.
Published: (2023-09-01)

Total neoadjuvant therapy for rectal cancer: evidence and challenge
by: Suk-Hwan Lee
Published: (2023-08-01)

The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
by: Lijin Zhang, et al.
Published: (2021-02-01)

Primary endocrine therapy of locally advanced breast cancer patients
by: Nešković-Konstantinović Zora B.
Published: (2003-01-01)

Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer
by: Jian Wang, et al.
Published: (2021-07-01)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
by: Hyder T, et al.
Published: (2021-03-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
by: Yi‐min Han, et al.
Published: (2023-06-01)

Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis
by: Wen Liu, et al.
Published: (2021-01-01)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
by: Wenwu He, et al.
Published: (2022-06-01)

Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma
by: Piotr J. Błoński, et al.
Published: (2024-03-01)

Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer
by: Nicola Simoni, et al.
Published: (2020-12-01)

Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
by: Long Pan, et al.
Published: (2019-12-01)

Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment
by: Hsu-Huan Chou, et al.
Published: (2021-03-01)

Impact of age on treatment response in men with prostate cancer treated with radiotherapy
by: Alex K. Bryant, et al.
Published: (2022-05-01)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
by: Anita De Rossi, et al.
Published: (2011-04-01)

Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials
by: Sergey Sychev, et al.
Published: (2023-08-01)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
by: Libo Yang, et al.
Published: (2018-03-01)

Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort
by: Guangyu Sun, et al.
Published: (2022-11-01)

Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery
by: Valerio Nardone, et al.
Published: (2022-06-01)

Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade
by: Le He, et al.
Published: (2022-09-01)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
by: Ailin Zhang, et al.
Published: (2021-11-01)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)